



THE COMPASS ROSE^{🇨🇦} ONCOLOGY FUND

Background

The **Compass Rose Oncology Fund** helps Ontario's cancer research innovators realize the commercial possibilities of their inventions. Funding is available to support development activities including proof-of-concept studies, validation, standard operating procedures, market analyses, IP protection and acquisition, expert guidance and management.

\$1M – \$5M

TYPICAL INVESTMENT
PER PROJECT

Project Preferences

- Cutting edge technology – transformative not incremental;
- Significant business opportunity – differentiated, competitive technology;
- Defined market segment;
- Regulatory strategy – clarity of the path, territories, time and capital required;
- Strong IP position – breadth, defensible, blocking ability, freedom to operate;
- Ability of funding to advance the technology to a value inflection point;
- Addresses an unmet need for cancer patients and/or cancer clinicians;
- Economic benefit to Ontario;
- Suitability of the team executing the work plan.

Conditions

The **Compass Rose Oncology Fund** is aimed at commercializing Ontario's cancer-related IP, arising from academic or non-academic sources. Investments typically range between \$1M and \$5M and are dispersed in tranches based on achieving pre-established milestones during the planned development. FACIT expects to make investments at a variety of funding levels and not all projects should or will receive this maximum allowable amount.

All investment requests will be reviewed by FACIT as well as appropriate external reviewers selected from academic and business communities.

This is an investment, not a grant. FACIT will receive consideration in the form of a royalty on commercialization revenues and/or equity in start-up companies, often in the form of a convertible debenture.

It is an objective of FACIT to encourage the maximum participation of Ontario organizations in the development, commercialization and utilization of inventions arising from FACIT investments.

Investment Request Process

For further details, please contact David Koehler at: david.koehler@facit.ca.

\$750M

Leveraged funding associated
with FACIT support

\$40M

Funding & equity
investments

48 Projects

at Ontario institutions or
start-ups supported by
FACIT funding

15 Companies

in Ontario created by
FACIT investments

About FACIT

FACIT builds companies with entrepreneurs to accelerate oncology innovation and its portfolio has attracted over 750 million dollars in investment to Ontario. Blending industry experience, capital and the unsurpassed clinician-scientist network of its strategic partner the Ontario Institute for Cancer Research (OICR), FACIT capitalizes on the province's investment in research and healthcare to the benefit of the local economy and patients worldwide. FACIT's commercialization portfolio includes Turnstone Biologics, Fusion Pharmaceuticals, Triphase Accelerator and other biotechnology organizations. *Cancer Breakthroughs. Realized.* facit.ca.

Contact us

facit.ca | info@facit.ca

FACIT | Cancer Breakthroughs.
Realized.